This clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229\_01 at fasting state.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
42
single dose administration (DA-1229 one tablet once a day)
single dose administration (DA-1229\_01-R one tablet once a day)
Bumin hospital
Seoul, South Korea
AUCt
Area Under the Curve
Time frame: pre-dose~72 hours post-dose
Cmax
Maximum Plasma Concentration
Time frame: pre-dose~72 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.